Focused on precision therapies for endocrine disorders, this biotech firm reported a notable insider buy amid a year of sharp ...

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 ...

CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no ...

Shares of newly IPO’ed peptide therapy developer MBX Biosciences (NASDAQ:MBX) traded sharply lower on Tuesday, even as several Wall Street firms launched its coverage with buy recommendations.

MBX Biosciences MBX, a clinical-stage biotech focused on developing treatments for endocrine and metabolic disorders, set terms for its initial public offering on Monday, with plans to offer 8.5 ...

MBX has fleshed out plans to take in over $136 million from its IPO as the biotech looks to bring a potential challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3. The ...

Revenue cycle management solutions provider MBX Medical Billing Experts has rolled out a new healthcare data analytics tool aimed at helping provider organizations maximize financial and operational ...

Positive results from MBX 1416 Phase 1 trial support Phase 2 advancement: In January 2025, the Company announced positive topline results from its Phase 1 single ascending dose and multiple ascending ...

$240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, ...